摘要
目的探讨对原发性肝癌患者实施血清AFP、CA19-9、CEA单项及三者联合检验的早期诊断及治疗价值。方法方便选择该院2015年10月—2017年10月间收治的60例肝癌患者(肝癌组)及60名健康体检人员(健康组),对所有人员实施血清AFP、CA19-9、CEA检测,分析两组人员检测结果。结果肝癌组患者AFP(321.5±38.7)μg/L、CA19-9(121.4±32.9)k U/L、CEA(20.8±4.5)μg/L较健康组(7.4±4.8)μg/L、(20.1±10.2)k U/L、(2.3±1.2)μg/L升高(P=0.000、0.000、0.000)。肝癌组患者AFP、CA19-9、CEA单独检测及联合检测阳性率63.3%、60.0%、71.7%、93.3%较健康组13.3%、25.0%、23.3%、38.3%均升高(P=0.000、0.000、0.000、0.000)。两组人员联合检测阳性率均高于单独检查。结论原发性肝癌实施血清AFP、CA19-9、CEA三者联合检验可便于患者早期诊断及治疗。
Objective To study the comparison of value of single serum AFP, CA19-9, CEA and the combination of the three in early diagnosis and treatment of primary liver cancer. Methods 60 cases of patients with liver cancer and 60 cases of healthy physical examination staff in our department from October 2015 to October 2017 were convenient selected, and the serum AFP, CA19-9, CEA of all staff were tested, and the test results of the two groups were analyzed. Results The AFP（321.5±38.7） μg/L, CA19-9（ 121.4±32.9） k U/L, CEA（ 20.8±4.5） μg/L of patients in the liver cancer group increased compared with those in the healthy group（7.4±4.8） μg/L,（20.1±10.2）k U/L,（2.3±1.2）μg/L（P=0.000, 0.000, 0.000）, and the positive rates of single test and combined test of AFP, CA19-9, CEA in the liver cancer group increased compared with those in the healthy group（63.3%, 60.0%, 71.7%,93.3% vs 13.3%, 25.0%, 23.3%, 38.3%）（P=0.000, 0.000, 0.000, 0.000）,and the positive rate of the combined test of the two groups was higher than that of the single examination. Conclusion The implementation of combined test of serum AFP, CA19-9, CEA in primary liver cancer patients contributes to the early diagnosis and treatment.
作者
苏英弟
SU Ying-di(Department of Clinical Laboratory,Second Affiliated Hospital of Guangxi University of Science and Technology,Liuzhou,Guangxi,545006 Chin)
出处
《中外医疗》
2018年第17期23-25,共3页
China & Foreign Medical Treatment
